Fundamental Analysis of FIBROGEN INC(NASDAQ:FGEN) stock

Fundamental Rating

FGEN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. FGEN has a bad profitability rating. Also its financial health evaluation is rather negative. FGEN is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year FGEN has reported negative net income.

In the past year FGEN has reported a negative cash flow from operations.

In the past 5 years FGEN always reported negative net income.

In the past 5 years FGEN reported 4 times negative operating cash flow.

1.2 Ratios

FGEN has a worse Return On Assets (-67.11%) than 63.25% of its industry peers.

		Industry Rank	Sector Rank
ROA	-67.11%
ROE	N/A
ROIC	N/A

ROA(3y)-50.91%

ROA(5y)-36.92%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

FGEN has a Gross Margin of 87.27%. This is amongst the best in the industry. FGEN outperforms 91.28% of its industry peers.

FGEN's Gross Margin has declined in the last couple of years.

FGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	87.27%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.8%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

FGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.

FGEN has more shares outstanding than it did 1 year ago.

FGEN has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, FGEN has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -7.40, we must say that FGEN is in the distress zone and has some risk of bankruptcy.

FGEN's Altman-Z score of -7.40 is on the low side compared to the rest of the industry. FGEN is outperformed by 70.77% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-7.4

ROIC/WACCN/A

WACC6.34%

2.3 Liquidity

FGEN has a Current Ratio of 1.52. This is a normal value and indicates that FGEN is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Current ratio, with a value of 1.52, FGEN is doing worse than 83.59% of the companies in the same industry.

FGEN has a Quick Ratio of 1.33. This is a normal value and indicates that FGEN is financially healthy and should not expect problems in meeting its short term obligations.

With a Quick ratio value of 1.33, FGEN is not doing good in the industry: 84.10% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.52
Quick Ratio	1.33

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 10.83% over the past year.

Looking at the last year, FGEN shows a small growth in Revenue. The Revenue has grown by 5.00% in the last year.

Measured over the past years, FGEN shows a decrease in Revenue. The Revenue has been decreasing by -7.05% on average per year.

EPS 1Y (TTM)10.83%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q18.57%

Revenue 1Y (TTM)5%

Revenue growth 3Y-5.72%

Revenue growth 5Y-7.05%

Revenue growth Q2Q-21.11%

3.2 Future

FGEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.04% yearly.

The Revenue is expected to grow by 8.97% on average over the next years. This is quite good.

EPS Next Y52.89%

EPS Next 2Y35.77%

EPS Next 3Y26.87%

EPS Next 5Y15.04%

Revenue Next Year-3.45%

Revenue Next 2Y1.64%

Revenue Next 3Y7.71%

Revenue Next 5Y8.97%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FGEN. In the last year negative earnings were reported.

Also next year FGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

FGEN's earnings are expected to grow with 26.87% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y35.77%

EPS Next 3Y26.87%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for FGEN!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

FIBROGEN INC

NASDAQ:FGEN (4/19/2024, 12:10:32 PM)

1.0899

-0.08 (-6.85%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap107.65M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-67.11%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	87.27%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.35

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.52
Quick Ratio	1.33
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)10.83%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y52.89%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)5%

Revenue growth 3Y-5.72%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

FIBROGEN INC (FGEN)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens